Contact The Gross Law Firm by March 25, 2025 Deadline to Join Class Action Against ESSA Pharma Inc.(EPIX)

1. EPIX faces a class action over misleading statements about its drug's efficacy. 2. Allegations include overstated clinical benefits of masofaniten combined with enzalutamide. 3. Class period for shareholders is from December 12, 2023, to October 31, 2024. 4. Shareholders can register without needing to lead the plaintiff filing. 5. Deadline to enroll as a lead plaintiff is March 25, 2025.

Legal

80

4m saved

Insight

Article

FAQ

Why Very Bearish?

The allegations of misleading information can lead to significant investor distrust, which historically results in stock price declines. For instance, similar cases in biotech sectors have led to major sell-offs.

How important is it?

The article details serious legal implications for EPIX, indicating potential financial repercussions and significant investor impact.

Why Short Term?

Immediate reactions to lawsuits often result in short-term stock volatility, as seen in previous legal cases impacting public perception and valuations swiftly.

Related Companies

XLRN AVEO NTRB

NEW YORK, March 10, 2025 /PRNewswire/ --

The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).

Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=134588&from=4

CLASS PERIOD:

December 12, 2023 to October 31, 2024

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times.

DEADLINE:

March 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/essa-pharma-inc-loss-submission-form/?id=134588&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of EPIX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 25, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018

Email: info@grosslawfirm.com

Phone: (646) 453-8903

SOURCE The Gross Law Firm